Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Western Europe

Western Europe Pharmaceuticals & Healthcare Insight provides country-by-country analysis of the key trends impacting the prescription, OTC and generic drugs industries across Western Europe. Western Europe Pharmaceuticals & Healthcare Insight includes competitive intelligence on the growth strategies of leading national and multinational companies, along with 5-year industry forecasts for each country. The service includes access to the very latest analysis, a searchable archive of articles and data and the ability to download PDFs of current and back issues.

›› To gain FREE online access for 14 days and to download a FREE PDF, click trial.

›› To receive 15 monthly pdf issues for the price of 12 and to gain immediate online access, click subscribe.


Latest Stories

Industry

GlaxoSmithKline (GSK) is a leading global manufacturer of prescription medicines and consumer healthcare products. The company has offices in over 100 countries and major research centres in the UK, US, Belgium and China. GSK's shares are listed on the London and New York Stock Exchanges and its corporate head office is located in the

2013-05-02

Italy / Industry

BMI View: Governments across Europe are focussing on cost containment. The consequent scrutiny on drug prices and medicine consumption will subsequently put pressure on companies and... 2013-02-22


Switzerland / Industry

BMI View: Novartis' U-turn over CEO Daniel Vasella's exit package could fuel support for a March 3 2013 referendum in Switzerland that proposes changes to Swiss corporate laws, including... 2013-02-20


Industry Developments

GlaxoSmithKline (GSK) is a leading global manufacturer of prescription medicines and consumer healthcare products. The company has offices in over 100 countries and major research centres... 2013-05-02


Italy

BMI View: Governments across Europe are focussing on cost containment. The consequent scrutiny on drug prices and medicine consumption will subsequently put pressure on companies and... 2013-02-22


Switzerland

BMI View: Novartis' U-turn over CEO Daniel Vasella's exit package could fuel support for a March 3 2013 referendum in Switzerland that proposes changes to Swiss corporate laws, including... 2013-02-20


Denmark

BMI View: The FDA rejection of Tresiba and Ryzodeg has led to a significant revision of earnings expectations for the market. Novo Nordisk's share price tumbled after February 12th.... 2013-02-19

Western Europe InsightWestern Europe Channels Western Europe Countries